Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Sidoti Csr issued their Q3 2025 earnings estimates for shares of Phio Pharmaceuticals in a report released on Wednesday, October 29th. Sidoti Csr analyst A. Hantman anticipates that the company will post earnings of ($0.44) per share for the quarter. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.77) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.26) EPS.
PHIO has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Phio Pharmaceuticals in a research note on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $14.00.
Phio Pharmaceuticals Stock Down 0.5%
Shares of NASDAQ PHIO opened at $2.05 on Monday. Phio Pharmaceuticals has a 52-week low of $0.97 and a 52-week high of $9.79. The firm has a fifty day moving average of $2.18 and a 200-day moving average of $2.21. The stock has a market capitalization of $11.74 million, a PE ratio of -0.63 and a beta of 0.95.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.09).
Institutional Investors Weigh In On Phio Pharmaceuticals
An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC grew its stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 38.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,694 shares of the company’s stock after purchasing an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 as of its most recent filing with the SEC. 57.31% of the stock is currently owned by institutional investors.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- Is Lemonade Stock Set for a Big Squeeze After Earnings?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Caterpillar Stock Could Top $650 by Year’s End
- 3 Small Caps With Big Return Potential
- ServiceNow’s 5-for-1 Split Is a Signal for Investors to Buy
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
